ArticleNutrients2025
Biological Age Acceleration Associated with the Progression Trajectory of Cardio-Renal-Metabolic Multimorbidity: A Prospective Cohort Study.
Article in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Trial
- MetaboHealth and Metabolic Vulnerability Index as Risk Factors for Cardio-Renal-Metabolic Multimorbidity: A Large-Scale Prospective Cohort Study.Diabetes, obesity & metabolism · 2026Article
- Phenotypic age metrics for risk stratification of chronic disease burden and all-cause mortality in adults.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Association between 24-h proteinuria and phenotypic age acceleration in adults with preserved kidney function: a cross-sectional study.International urology and nephrology · 2026Article
- Biological age acceleration and extrahepatic multimorbidity in U.S. adults with metabolic dysfunction-associated steatotic liver disease: a national cross-sectional study.Clinical and experimental hepatology · 2026Article
- Accelerometer-derived "weekend warrior" physical activity pattern and trajectory of cardio-renal-metabolic multimorbidity: a multi-state analysis in the UK Biobank.BMC public health · 2026Article
- Age-Stratified Differences in Cardio-Reno-Metabolic Risk Profiles.Geriatrics (Basel, Switzerland) · 2026Article
- Interpretable Prediction of Late-Stage CKM Syndrome Association From Dietary Nutrients in Accelerated Aging Using SHAP and LIME.Food science & nutrition · 2026Article
- Association of pregnancy history and unhealthy lifestyle with biological age acceleration: a large cross-sectional study.Frontiers in public health · 2026Article
- Accelerated biological aging and incident degenerative valvular heart disease: Findings from 408,783 UK Biobank participants.International journal of cardiology. Heart & vasculature · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesPrevious studies have confirmed that biological age (BA) acceleration is associated with single cardio-renal-metabolic diseases (CRMDs), typically including type 2 diabetes mellitus, cardiovascular disease, and chronic kidney disease. However, its association with progression to cardio-renal-metabolic multimorbidity (CRMM, coexistence of ≥2 CRMDs) and subsequent mortality remains unexplored.
methodsUsing the multi-state model, we analyzed 278,927 UK Biobank participants free of CRMDs at baseline to investigate the association between BA acceleration-measured by phenotypic age (PhenoAge) and Klemera-Doubal method age (KDMAge)-and CRMM progression trajectory, from health to the first CRMD and then to CRMM and death. BA acceleration was the residual from regressing BA on chronological age; positive values indicated a biologically older individual.
resultsPhenoAge acceleration showed stronger associations than KDMAge acceleration. Per the 1-SD increase in PhenoAge acceleration; HRs (95% CIs) were observed at 1.18 (1.17-1.19) for baseline to first CRMD; 1.24 (1.22-1.26) for first CRMD to CRMM; 1.25 (1.22-1.27) for baseline to death; 1.13 (1.11-1.15) for first CRMD to death; and 1.09 (1.06-1.12) for CRMM to death. Biologically older individuals by PhenoAge acceleration showed greater reductions in CRMD-free and total life expectancy than those by KDMAge acceleration. Age, socioeconomic status, education, smoking status, alcohol consumption, physical activity, and diet-modified risks for specific transitions.
conclusionsBA acceleration, particularly PhenoAge acceleration, relates to higher CRMM progression risk and shorter life expectancy. Combining BA acceleration with sociodemographic or lifestyle factors improves risk identification for specific transitions. BA acceleration offers the potential to guide CRMM prevention across its entire progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.